English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Germline single nucleotide polymorphisms in the promoter region of the  DCBLD1  gene are associated with non-smoking cases of both non-small cell lung carcinoma (NSCLC) and human papillomavirus-negative head and neck cancer. However the clinical relevance and function of  DCBLD1  remain unclear. This multicenter retrospective study was designed to evaluate the prognostic value and function of  DCBLD1  in the four main solid cancers: NSCLC, invasive breast carcinoma, colorectal adenocarcinoma and prostate adenocarcinoma. We included the following cohorts: GSE81089 NSCLC, METABRIC invasive breast carcinoma, GSE14333 colorectal adenocarcinoma, GSE70770 prostate adenocarcinoma and The Cancer Genome Atlas (TCGA) Firehose Legacy cohorts of all four cancers.  DCBLD1  gene expression was associated with a worse overall survival in multivariate analyses for both NSCLC cohorts (TCGA:  P  = 0.03 and GSE81089:  P  = 0.04) and both invasive breast carcinoma cohorts (TCGA:  P  = 0.02 and METABRIC:  P  < 0.001). Patients with high  DCBLD1  expression showed an upregulation of the integrin signaling pathway in comparison to those with low  DCBLD1  expression in the TCGA NSCLC cohort (FDR = 5.16 × 10 –14 ) and TCGA invasive breast carcinoma cohort (FDR = 1.94 × 10 –05 ).

DCBLD1 is associated with the integrin signaling pathway and has prognostic value in non-small cell lung and invasive breast carcinoma